Keith A. Goldan - Feb 2, 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Financial Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Feb 2, 2023
Transactions value $
$3,140,500
Form type
4
Date filed
2/3/2023, 04:00 PM
Previous filing
Jun 15, 2022
Next filing
Jun 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $3.14M +110K $28.55 110K Feb 2, 2023 Common Stock 110K $28.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option shall vest monthly over a four-year period.